RxDoctor Payments Data

Laura Odom

Family · San Angelo, TXNPI 1528436243

Payments from drug & device makers

$1,477in general payments, 2019–2025

Across 70 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$362
  • Novo Nordisk$325
  • Alkermes, Inc.$164
  • Lilly USA, LLC$163
  • Boehringer Ingelheim$56
  • Dexcom, Inc.$52
  • plus $355 from 15 others

What the payments were for

  • Food & beverage$1,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,477 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$150,610
MounjaroTirzepatide77$103,874
RybelsusSemaglutide33$78,079
Tresiba Flextouch U-100Insulin Degludec28$41,068
TradjentaLinagliptin32$40,599
JanuviaSitagliptin Phosphate24$38,230
JardianceEmpagliflozin18$22,012
Tresiba Flextouch U-200Insulin Degludec22$17,191
Levemir FlexpenInsulin Detemir28$13,060
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,902
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$7,966
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$5,429
VascepaIcosapent Ethyl11$5,128
Gabapentin137$3,901
Atorvastatin Calcium416$3,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$325$228,689133 claims
Lilly USA, LLCMounjaro$163$103,87477 claims
Boehringer IngelheimTradjenta, Jardiance$56$62,61250 claims
MerckJanuvia$34$38,23024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →